Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab']
highly pretreated lbcl patients achieved durable responses with glofitamab and retreatment could be an option in those patients who progressed after eot #ash22 #immunotherapy #clinicaltrials #bites #glofitamab 
Hematologist, MD
Vall d'Hebron Hospital